Medicalgorithmics Stock

Medicalgorithmics Revenue

The The revenue of Medicalgorithmics (MDG.WA) as of Jul 15, 2026 is 24.00 M PLN. In the previous year, The revenue was 43.10 M PLN — a change of -44.31% (lower).

Revenue

24.00 MPLN

YoY

-44.31%

Last updated:

In 2026, Medicalgorithmics's sales reached 24.00 M PLN, a -44.31% difference from the 43.10 M PLN sales recorded in the previous year.

Over the last 13 years Medicalgorithmics grew revenue by 11.5% annually, reaching 24.00 M PLN.

The Medicalgorithmics Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

REVENUE (M PLN)
GROSS MARGIN (%)
Date
REVENUE (M PLN)
GROSS MARGIN (%)
Jan 1, 2021
48.35 base
79.49 base
Jan 1, 2022
62.72 base
80.30 base
Jan 1, 2023
43.10 base
83.22 base
Jan 1, 2024
24.00 base
84.86 base
Jan 1, 2025 (e)
30.87 base
65.99 base
Jan 1, 2026 (e)
57.66 base
35.33 base
Jan 1, 2027 (e)
76.87 base
26.50 base
Jan 1, 2028 (e)
97.73 base
20.84 base
YEARREVENUE (M PLN)GROSS MARGIN (%)
2028 est 97.7320.84
2027 est 76.8726.50
2026 est 57.6635.33
2025 est 30.8765.99
2024 24.0084.86
2023 43.1083.22
2022 62.7280.30
2021 48.3579.49
2020 111.73-30.18
2019 173.871.20
2018 199.4016.80
2017 203.3522.96
2016 127.9217.57
2015 49.3342.34
2014 29.7146.33
2013 15.7063.06
2012 11.0063.64
2011 5.8051.72
Access this data via the Eulerpool API

Medicalgorithmics Revenue

Medicalgorithmics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
48.35 M PLN
12.13 M PLN
-180.64 M PLN
Jan 1, 2022
62.72 M PLN
16.02 M PLN
-11.86 M PLN
Jan 1, 2023
43.10 M PLN
552,000.00 PLN
-578,000.00 PLN
Jan 1, 2024
24.00 M PLN
-13.86 M PLN
-16.08 M PLN
Jan 1, 2025 (e)
30.87 M PLN
-10.22 M PLN
-10.90 M PLN
Jan 1, 2026 (e)
57.66 M PLN
4.99 M PLN
1.36 M PLN
Jan 1, 2027 (e)
76.87 M PLN
9.73 M PLN
5.43 M PLN
Jan 1, 2028 (e)
97.73 M PLN
16.50 M PLN
11.44 M PLN

Medicalgorithmics Margins

Medicalgorithmics stock margins

The Medicalgorithmics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Medicalgorithmics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Medicalgorithmics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
79.49 %
25.09 %
-373.61 %
Jan 1, 2022
80.30 %
25.55 %
-18.91 %
Jan 1, 2023
83.22 %
1.28 %
-1.34 %
Jan 1, 2024
84.86 %
-57.76 %
-67.00 %
Jan 1, 2025 (e)
84.86 %
-33.10 %
-35.33 %
Jan 1, 2026 (e)
84.86 %
8.66 %
2.35 %
Jan 1, 2027 (e)
84.86 %
12.65 %
7.06 %
Jan 1, 2028 (e)
84.86 %
16.89 %
11.71 %

Medicalgorithmics Stock analysis

What does Medicalgorithmics do? Medicalgorithmics is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Medicalgorithmics's Sales Figures

The sales figures of Medicalgorithmics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Medicalgorithmics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Medicalgorithmics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Medicalgorithmics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Medicalgorithmics stock

The revenue of Medicalgorithmics is 24.00 M PLN in 2026.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Medicalgorithmics

All Key Metrics — Medicalgorithmics